These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 34746975)

  • 21. Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD.
    Chen JL; Wu CY; Luo XY; Wang XY; Wang FM; Huang X; Yuan W; Guo Q
    Sci Rep; 2024 May; 14(1):11782. PubMed ID: 38782996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
    Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
    Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of the association between tumor-infiltrating immune cells and the prognosis of lung adenocarcinoma.
    Pan Y; Sha Y; Wang H; Zhuang H; Ren X; Zhu X; Wei X
    J Cancer Res Ther; 2020; 16(2):320-326. PubMed ID: 32474519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in Immunological Landscape between
    Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
    Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
    Zhang X; Wu Z; Ma K
    BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of EMG1 in lung adenocarcinoma progression: Implications for prognosis and immune cell infiltration.
    Wu X; Wu Z; Xie Z; Huang H; Wang Y; Lv K; Yang H; Liu X
    Int Immunopharmacol; 2024 Sep; 138():112553. PubMed ID: 38943975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
    Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
    Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration.
    Xu Y; Jiang Q; Liu H; Xiao X; Yang D; Saw PE; Luo B
    J Immunol Res; 2020; 2020():8835393. PubMed ID: 33490290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
    Wei T; Song J; Liang K; Li L; Mo X; Huang Z; Chen G; Mao N; Yang J
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1049-1064. PubMed ID: 33387038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
    Budczies J; Kirchner M; Kluck K; Kazdal D; Glade J; Allgäuer M; Kriegsmann M; Heußel CP; Herth FJ; Winter H; Meister M; Muley T; Goldmann T; Fröhling S; Wermke M; Waller CF; Tufman A; Reck M; Peters S; Schirmacher P; Thomas M; Christopoulos P; Stenzinger A
    Cancer Immunol Immunother; 2022 Feb; 71(2):251-265. PubMed ID: 34125345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The Expression of RTN1 in Lung Adenocarcinoma and 
Its Effect on Immune Microenvironment].
    Zhu S; Zu L; Xu S
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
    Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
    Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.